



CORE BRIEF TO MANAGEMENT GROUP MEMBERS

MEETING HELD ON 23 SEPTEMBER 2021

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

1. Welcome and Introductions

The Chair welcomed members to the meeting noting that, due to the COVID-19 pandemic, the meeting was being held via MS Teams. It was noted that a quorum had been achieved.

Written questions from members and answers had been published in advance of the meeting and had been embedded within the meeting papers.

2. Action Log

Members received an update on progress against the action log and **noted** the updates.

3. Managing Director's Report

Members received the Managing Director's Report and **noted** updates on:

- Inherited White Matters Disorder (IWMD),
- Syndrome Without a Name (SWAN),
- Commissioning Future New Services for Mid, South and West Wales, specifically relating to requests from the NHS Wales Collaborative (Collaborative) for WHSSC to:
 - Commission Hepato-Pancreato-Biliary Services;
 - Commission the Hepato-Cellular Carcinoma (HCC) MDT
 - develop a specialist orthopaedic paediatric service specification with a view to future commissioning of the service,
- A request was also received from the CEOs of Swansea Bay and Cardiff and Vale University Health Boards (HBs) on behalf of the Collaborative to commission a spinal services operational delivery network (ODN) on behalf of the six HBs in Mid, South and West Wales,
- The Workforce capacity report considered by the Joint Committee on the 7 September 2021,
- a workshop will be held to evaluate the national and local commissioning of services to coincide with a MG meeting in November /December,

- High cost bespoke packages of care for Complex Mental Health Patients.

4. Funding Release for Implementation of 2021/22 Paediatric Cystic Fibrosis Integrated Commissioning Plan (ICP) Scheme

Members received a report requesting approval for the release of funding to enable implementation of the 2021/22 ICP scheme for pharmacy support to the paediatric cystic fibrosis service in south Wales.

Members **(1) Noted** that the requested funding was within the provision made for paediatric cystic fibrosis as an in-year risk within the ICP 2021-24; **(2) Supported** the release of funding for the ICP scheme for paediatric cystic fibrosis service in south Wales.

5. Syndrome Without a Name (SWAN) Service: Project Initiation Document

Members received a report requesting consideration of the Terms of Reference (ToR) for the SWAN pilot evaluation Task and Finish Group (T&F Group).

Members **(1) Agreed** the preferred membership for the evaluation of the SWAN Pilot.

6. Bariatric Surgery – Current and Future Provision

Members received a report outlining the current situation regarding the delivery of the Level 4 Bariatric Surgery services for Welsh residents, the potential increase in demand and which sought support to scope out the potential for a further designated provider.

Members **(1) Supported** the recommendation to scope the potential for an additional designated provider for Level 4 Bariatric Surgery; and **(2) Noted** the information presented within the report

7. Major Trauma Priorities for in year use of Underspend and Resource Plan for 2022

Members received a report providing an update following the Joint Committee meeting 7 September 2021 regarding the use of the non-recurrent underspend in the major trauma allocation; and which sought support from the MG on the priorities for the use of the underspend.

Members discussed utilising the non-recurrent underspend across the network for priorities rather than solely in the major trauma centre.

Members **(1) Noted** the Joint Committee's discussion on Major Trauma Priorities for in year use of Underspend and Resource Plan for 2022 at its meeting on the 7 September 2021; **(2) Noted** that the Management Group has been given delegated authority on making a recommendation to the Joint Committee on the use of the underspend; **(3) Discussed** the priorities for the use of the underspend; **(4) Noted** the preferred option recommended by the WHSS Team and;

(5) **Supported** the use of the underspends for the priorities identified across the Network on a non-recurrent basis; and (6) **Noted** that the Management Group have been asked to undertake further work regarding any other areas they wished to see included in the ICP, and the relative priority of those areas compared to other proposals in the plan

8. Commissioning Assurance Framework

Members received a report which presented the Commissioning Assurance Framework (CAF) and the supporting suite of documents for information.

Members noted that the Integrated Commissioning Plan (ICP) 2021-2022 was presented to the Joint Committee on 09 March 2021, a final draft of the ICP was considered and approved by Joint Committee at the Extraordinary Meeting on 16 February 2021, Section 13 of the ICP outlined that a new Commissioning Assurance Framework (CAF) would be introduced in 2021-2022 which would be supported by a Performance Assurance Framework, Risk Management Strategy, Escalation Process and a Patient Engagement & Experience Framework.

Members noted that the WHSSC Quality and Patient Safety Committee had endorsed the CAF and supporting document on the 10 August and that the Joint Committee had approved them on the 7 September 2021.

Members (1) **noted** the report.

9. Recovery Planning Presentation– Quality and Outcome Improvement for Patients

Members received an informative presentation providing an update on WHSSC's approach to recovery planning with a particular emphasis on quality and outcome improvement for patients.

Members (1) **noted** the presentation.

10. WHSSC Prioritisation Panel Results 2021-2022

Members received a report presenting the final, validated results from the Prioritisation Panel to inform development of the WHSSC Integrated Commissioning Plan (ICP) for 2022-2025.

Members (1) **Noted** the information presented within the report; (2) **Endorsed** the process for determining the priority of new treatment interventions; and (3) **Supported** the recommendations of the WHSSC Prioritisation Panel.

11. Integrated Commissioning Plan 2022-2025 Financial Summary

Members received a presentation outlining the financial planning assumptions for the Integrated Commissioning Plan 2022-2025.

Members (1) **noted** the presentation.

12. COVID-19 Activity Report for Month 4 2021-2022

Members received a report highlighting the scale of the decrease in activity delivered for the Welsh population by providers in England, together with the two major supra-regional providers in South Wales.

Members noted the decrease in activity during the peak COVID-19 periods, which informed the level of potential harms to specialised services patients, the loss of financial value from the necessary national block contracting arrangements introduced to provide overall system stability, recovery rates, and access comparisons across HBs.

Members (1) **noted** the report.

13. Financial Performance Report - Month 5 2021-22

Members received the Financial Performance Report for Month 5 which provided the current financial position of WHSSC together with the outturn forecast for the financial year. The financial position reported at Month 5 for WHSSC is a year-end outturn forecast under spend of £7,146k.

Members **noted** that the under spend predominantly related to the slippage of planned developments, handback of 50% of the COVID-19 recovery funding and releasable reserves from 2020-2021 provisions. There is a partial cost pressure offset with the over spend in Independent Patient Funding Requests (IPFR) and Mental Health due to high Children and Adolescent Mental Health Services (CAMHS) out of area activity and complex Learning Disability (LD) patient placements.

Members (1) **noted** the current financial position and forecast year-end position.

